HEALTHCARE RESOURCE UTILISATION AMONG CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA PATIENTS– FINDINGS FROM THE FIRST INTERNATIONAL BURDEN OF ILLNESS STUDY (ASSURE-CSU)

Author(s)

Tian H1, Chambenoit O2, Chiva-Razavi S2, Lynde C3, Sussman G4, Chapman-Rothe N5, Weller K6, Koenders J7, Knulst AC8, Elberink JN9, Halliday A10, Alexopoulos ST10, Nakonechna A11, Grattan C12, Abouzakouk M11, Sweeney C13, Radder C13, Wolin D14, McBride D15, Hollis K13, Balp M16, Maurer M6
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Lynderm Research Inc., Toronto, ON, Canada, 4St Michael's Hospital, University of Toronto, Toronto, ON, Canada, 5Novartis Pharma GmbH, Nuernberg, Germany, 6Charite - Universitätsmedizin Berlin, Berlin, Germany, 7Novartis Pharma B.V., Arnhem, The Netherlands, 8University Medical Center Utrecht, Utrecht, The Netherlands, 9Unviersity Medical Center Groningen, Groningen, The Netherlands, 10Novartis Pharmaceuticals UK Limited, Surrey, UK, 11Hull and East Yorkshire NHS Hospital Trust, Hull, UK, 12Norfolk and Norwich University Hospital, Norwich, UK, 13RTI Health Solutions, Research Triangle Park, NC, USA, 14RTI Health Solutions, Ann Arbor, MI, USA, 15RTI Health Solutions, Manchester, UK, 16Novartis Pharma AG, Basel, Switzerland

Presentation Documents

OBJECTIVES: There are limited data on healthcare resource utilisation associated with inadequately controlled chronic spontaneous (idiopathic) urticaria (CSU/CIU) patients. ASSURE-CSU is an observational, multinational study conducted to identify and quantify burden of illness in these patients. Data on resource utilisation for Canada, Germany, UK and the Netherlands are summarised.  METHODS: This study included a 1-year retrospective medical record abstraction and a cross-sectional patient-reported outcomes survey. Adult CSU/CIU patients with disease persisting for ≥12 months despite treatment were assessed. Data on resource utilisation were extracted from patient medical records, and reported descriptively. RESULTS: Medical records were abstracted for 99 patients each in Canada and the Netherlands, 100 in Germany and 83 in the UK. In Canada, 83% patients had one or more visits to a health care professional (HCP) with a total mean (SD) of 3.1 (2.57) annual visits. In the prior 12 months, visits to allergists and dermatologists were reported by 72% and 11% patients. In Germany, 52% patients visited HCPs [annual visits: 3.3 (3.81)]. Hospitalisations and emergency room (ER) visits were reported by 18% and 15% patients. Allergists and dermatologists were visited by 33% and 31% patients. In UK, 86% patients visited HCPs [annual visits: 3.7 (2.68)]. Dermatologists were seen by 54% patients, allergists by 30% and hospital nurses by 10%. HCPs were visited by 87% patients in the Netherlands [annual visits: 4.1 (3.87)]. Visits to dermatologists, allergists and other consultants were reported by 51%, 42% and 13% patients. ER visits and hospitalisations were less frequent in Canada, the UK and the Netherlands compared with Germany. CONCLUSIONS: This is the first study to quantify resource utilisation associated with inadequately controlled CSU/CIU. The types of medical resources differ among the countries depending on the local healthcare specificities. Resource utilisation pattern was primarily outpatient but varied across countries.

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PSS52

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Sensory System Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×